MGMT gene promoter methylation in humoral tissue as biomarker for lung cancer diagnosis: An update meta‐analysis

Abstract Objective To investigate O‐6‐methylguanine‐DNA methyltransferase (MGMT) gene promoter methylation in humoral tissue as biomarker for lung cancer diagnosis by pooling relevant open published data. Methods Clinical studies relevant to MGMT gene promoter methylation and lung cancer were system...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bizheng Chen, Xiaozhen Ying, Liming Bao
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	biomarker lung cancer diagnosis meta‐analysis MGMT gene promoter methylation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/9eae6dbdf0534983bab8a15a58db5472
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9eae6dbdf0534983bab8a15a58db5472
record_format	dspace
spelling	oai:doaj.org-article:9eae6dbdf0534983bab8a15a58db54722021-12-02T02:34:55ZMGMT gene promoter methylation in humoral tissue as biomarker for lung cancer diagnosis: An update meta‐analysis1759-77141759-770610.1111/1759-7714.14186https://doaj.org/article/9eae6dbdf0534983bab8a15a58db54722021-12-01T00:00:00Zhttps://doi.org/10.1111/1759-7714.14186https://doaj.org/toc/1759-7706https://doaj.org/toc/1759-7714Abstract Objective To investigate O‐6‐methylguanine‐DNA methyltransferase (MGMT) gene promoter methylation in humoral tissue as biomarker for lung cancer diagnosis by pooling relevant open published data. Methods Clinical studies relevant to MGMT gene promoter methylation and lung cancer were systematic electronic searched in the databases of Medline, EMBASE, Ovid, Web of Science, and CNKI. Data of true positive (tp), false positive (fp), false negative (fn), and true negative (tn) were extracted from the included studies and made combination. The diagnostic sensitivity, specificity, diagnostic odds ratio (DOR) and summary receiver operating characteristic (SROC) of MGMT gene methylation for lung cancer diagnosis were pooled. Results Twelve studies were included in the meta‐analysis. The diagnostic sensitivity, specificity, DOR were 0.39 (95% CI = 0.31–0.49) 0.92 (95% CI = 0.77–0.97), and 4.20 (95% CI = 2.09–8.44), respectively under random effect model. The SROC of MGMT gene methylation for lung cancer diagnosis was 0.58 (95% CI = 0.53–0.62). Conclusion MGMT methylation rate was higher in plasma and bronchoalveolar lavage fluid (BLAF) of lung cancer cases compared to controls. High diagnostic specificity indicated that MGMT methylation in plasma and BLAF can be applied as lung cancer confirmation test.Bizheng ChenXiaozhen YingLiming BaoWileyarticlebiomarkerlung cancer diagnosismeta‐analysisMGMT genepromoter methylationNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENThoracic Cancer, Vol 12, Iss 23, Pp 3194-3200 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	biomarker lung cancer diagnosis meta‐analysis MGMT gene promoter methylation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	biomarker lung cancer diagnosis meta‐analysis MGMT gene promoter methylation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Bizheng Chen Xiaozhen Ying Liming Bao MGMT gene promoter methylation in humoral tissue as biomarker for lung cancer diagnosis: An update meta‐analysis
description	Abstract Objective To investigate O‐6‐methylguanine‐DNA methyltransferase (MGMT) gene promoter methylation in humoral tissue as biomarker for lung cancer diagnosis by pooling relevant open published data. Methods Clinical studies relevant to MGMT gene promoter methylation and lung cancer were systematic electronic searched in the databases of Medline, EMBASE, Ovid, Web of Science, and CNKI. Data of true positive (tp), false positive (fp), false negative (fn), and true negative (tn) were extracted from the included studies and made combination. The diagnostic sensitivity, specificity, diagnostic odds ratio (DOR) and summary receiver operating characteristic (SROC) of MGMT gene methylation for lung cancer diagnosis were pooled. Results Twelve studies were included in the meta‐analysis. The diagnostic sensitivity, specificity, DOR were 0.39 (95% CI = 0.31–0.49) 0.92 (95% CI = 0.77–0.97), and 4.20 (95% CI = 2.09–8.44), respectively under random effect model. The SROC of MGMT gene methylation for lung cancer diagnosis was 0.58 (95% CI = 0.53–0.62). Conclusion MGMT methylation rate was higher in plasma and bronchoalveolar lavage fluid (BLAF) of lung cancer cases compared to controls. High diagnostic specificity indicated that MGMT methylation in plasma and BLAF can be applied as lung cancer confirmation test.
format	article
author	Bizheng Chen Xiaozhen Ying Liming Bao
author_facet	Bizheng Chen Xiaozhen Ying Liming Bao
author_sort	Bizheng Chen
title	MGMT gene promoter methylation in humoral tissue as biomarker for lung cancer diagnosis: An update meta‐analysis
title_short	MGMT gene promoter methylation in humoral tissue as biomarker for lung cancer diagnosis: An update meta‐analysis
title_full	MGMT gene promoter methylation in humoral tissue as biomarker for lung cancer diagnosis: An update meta‐analysis
title_fullStr	MGMT gene promoter methylation in humoral tissue as biomarker for lung cancer diagnosis: An update meta‐analysis
title_full_unstemmed	MGMT gene promoter methylation in humoral tissue as biomarker for lung cancer diagnosis: An update meta‐analysis
title_sort	mgmt gene promoter methylation in humoral tissue as biomarker for lung cancer diagnosis: an update meta‐analysis
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/9eae6dbdf0534983bab8a15a58db5472
work_keys_str_mv	AT bizhengchen mgmtgenepromotermethylationinhumoraltissueasbiomarkerforlungcancerdiagnosisanupdatemetaanalysis AT xiaozhenying mgmtgenepromotermethylationinhumoraltissueasbiomarkerforlungcancerdiagnosisanupdatemetaanalysis AT limingbao mgmtgenepromotermethylationinhumoraltissueasbiomarkerforlungcancerdiagnosisanupdatemetaanalysis
_version_	1718402365988536320

MGMT gene promoter methylation in humoral tissue as biomarker for lung cancer diagnosis: An update meta‐analysis

Ejemplares similares